tocentecan (M9140, Precemtabart) anti-CEACAM5 ADC

tocentecan · Merck Healthcare KGaA

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for tocentecan (M9140, Precemtabart) anti-CEACAM5 ADC, covering 2026-04-23 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors [Phase 1]